Xin Lang Cai Jing·2025-12-08 07:56Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has successfully negotiated to include Amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective from January 1, 2026, to December 31, 2027 [1] Group 1 - Amisulpride orally disintegrating tablets are a modified formulation of Amisulpride tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - As of the date of the announcement, there are no other companies in China that have listed Amisulpride orally disintegrating tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]